cridanimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
immunomodulators, both stimulant/suppressive and stimulant 4853 38609-97-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cridanimod
  • neovir
  • sodium cridanimod
  • oxodihydroacridinylacetate sodium
A small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Upon intramuscular administration, cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells. In addition, this agent is able to increase the production and release of interferon (IFN) alpha and beta. PR is often downregulated in endometrial cancer and makes it resistant to progestin-mediated hormone therapy.
  • Molecular weight: 253.26
  • Formula: C15H11NO3
  • CLOGP: 1.31
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 57.61
  • ALOGS: -3.11
  • ROTB: 2

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AX18 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Other immunostimulants

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.63 acidic
pKa2 1.78 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Trypsin Enzyme AC50 5.15 CHEMBL
Stimulator of interferon genes protein Unclassified Kd 5.48 CHEMBL

External reference:

IDSource
D10507 KEGG_DRUG
CHEBI:136036 CHEBI
CHEMBL1569545 ChEMBL_ID
C077681 MESH_SUPPLEMENTAL_RECORD_UI
DB13674 DRUGBANK_ID
C0044659 UMLSCUI
1K5 PDB_CHEM_ID
8018 INN_ID
38072 PUBCHEM_CID
X91E9EME19 UNII

Pharmaceutical products:

None